David Pace

Summary

Affiliation: University of Oxford
Country: Malta

Publications

  1. ncbi Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 92:909-15. 2007
  2. ncbi MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Tal Qroqq, Msida, MSD 2090, Malta
    Curr Opin Mol Ther 11:692-706. 2009
  3. ncbi Quadrivalent meningococcal conjugate vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 27:B30-41. 2009
  4. ncbi Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Expert Rev Vaccines 8:529-42. 2009
  5. ncbi Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, MSD, Malta
    Vaccine 26:5952-6. 2008
  6. ncbi A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
    D Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 93:963-70. 2008
  7. ncbi Quest for the diagnosis. Case 1: a neonatal zoonosis. Neonatal Pasteurella multocida septicaemia
    David Pace
    Department of Paediatrics, St Luke's Hospital, Guardamangia, Malta
    Acta Paediatr 97:250-2. 2008
  8. ncbi A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
    Pediatr Infect Dis J 26:1057-9. 2007
  9. ncbi Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    Matthew D Snape
    Oxford Vaccine Group, University of Oxford, England
    JAMA 299:173-84. 2008
  10. ncbi Meningococcal disease: clinical presentation and sequelae
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 30:B3-9. 2012

Detail Information

Publications13

  1. ncbi Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 92:909-15. 2007
    ..This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis...
  2. ncbi MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Tal Qroqq, Msida, MSD 2090, Malta
    Curr Opin Mol Ther 11:692-706. 2009
    ....
  3. ncbi Quadrivalent meningococcal conjugate vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 27:B30-41. 2009
    ..This vaccine and others in development offer the potential to broaden population protection against meningococcal disease...
  4. ncbi Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Expert Rev Vaccines 8:529-42. 2009
    ..This article discusses this novel quadrivalent vaccine formulation and its potential to control invasive disease caused by N. meningitidis serogroups A, C, Y and W-135...
  5. ncbi Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, MSD, Malta
    Vaccine 26:5952-6. 2008
    ....
  6. ncbi A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
    D Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, UK
    Arch Dis Child 93:963-70. 2008
    ....
  7. ncbi Quest for the diagnosis. Case 1: a neonatal zoonosis. Neonatal Pasteurella multocida septicaemia
    David Pace
    Department of Paediatrics, St Luke's Hospital, Guardamangia, Malta
    Acta Paediatr 97:250-2. 2008
  8. ncbi A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
    Pediatr Infect Dis J 26:1057-9. 2007
    ..SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT...
  9. ncbi Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    Matthew D Snape
    Oxford Vaccine Group, University of Oxford, England
    JAMA 299:173-84. 2008
    ..However, the currently licensed vaccine is poorly immunogenic in infancy, when the highest rates of disease are observed...
  10. ncbi Meningococcal disease: clinical presentation and sequelae
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 30:B3-9. 2012
    ..The only rational approach to the prevention of meningococcal disease and the associated human suffering is through vaccination...
  11. ncbi Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Future Microbiol 5:1629-40. 2010
    ..In Europe, MenACWY-CRM is the first quadrivalent meningococcal glycoconjugate vaccine available to provide broader protection against Neisseria meningitidis serogroups A, C, W-135 and Y...
  12. ncbi Adequacy of pediatric triage
    Pharrah Debono
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Disaster Med Public Health Prep 6:151-4. 2012
    ..To assess the adequacy of the pediatric triage system in an acute care general hospital...
  13. ncbi Manifestations of paediatric Leishmania infantum infections in Malta
    David Pace
    Paediatric Infectious Diseases Clinic, Mater Dei Hospital, Msida, Malta
    Travel Med Infect Dis 9:37-46. 2011
    ..Leishmaniasis should be included in the differential diagnosis of fever and hepatosplenomegaly or chronic cutaneous lesions in children who travel to Malta...